Company intelligence / Profile preview
SmartNuclide
- Ownership
- Private
- Employees
- ~100
- Development stage
- Other
Overview
SmartNuclide has commercialized its recombinant human thyroid stimulating hormone product in China and is advancing multiple innovative radioactive diagnostic and therapeutic products through clinical development. Its lead radioactive diagnostic agents are in early clinical trials, including a PD-L1-targeted nanobody tracer that has received IND approval from the US FDA. The company’s pipeline includes more than ten programs spanning preclinical to clinical stages, primarily focused on oncology indications such as solid tumors and differentiated thyroid carcinoma.
- Therapeutic areas
- Oncology
- Modalities
- Recombinant proteinMonoclonal antibody fragmentRadiopharmaceuticalRadioactive imaging agentRadioactive therapeutic agent
- Industry
- Biotech
Drug pipeline
18 assets17 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on SmartNuclide.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SmartNuclide.